Thousands demand Spinraza to be made available for adults in Croatia

Thousands of people are taking to streets across Croatia. The reason is that Spinraza, the life-saving treatment for spinal muscular atrophy, is not available there for adults living with SMA.

In the small town of Omiš, almost 10% of its 14,000-strong population battled wind and snow, protesting on the town’s main square on 9 January. People demanded that Nora, a 22-year old with SMA, is allowed access to Spinraza. Hundreds more have been demonstrating country-wide since autumn 2018 for the same cause: to demand wide access to the break-through Spinraza treatment.

Meanwhile, the country’s health minister Milan Kujundžić claimed repeatedly that there is no evidence of the drug’s efficacy in adults.

Croatia has been providing Spinraza as a standard treatment since early 2018. However, access to the drug is limited to people under 18.

https://radio.hrt.hr/aod/kriteriji-za-spinrazu/283850

Latest Posts

  • Calling on all the community to ACT NOW to avoid losing treatments!

    Calling on all the community to ACT NOW to avoid losing treatments!

    Currently, there are two approved treatments for SMA: risdiplam and nusinersen. These treatments were initially approved temporarily under Managed Access Agreements while the NHS and NICE gathered data to assess their cost-effectiveness. Now, as these agreements come to an end, both treatments face a crucial review.

    Read more

  • NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    SMA UK are proud to join together with Treat SMA and MDUK to bring you this webinar about NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam. 2024 sees the end of the managed access agreements (MAAs) for the two treatments. An expert committee will gather to assess the new clinical and real-world evidence, along…

    Read more

  • Let the battle begin

    Let the battle begin

    This year the Managed Access Agreement for Spinraza and Risdiplam expires. The MAA was put in place five years ago so the pharmaceutical companies could gather more evidence to resubmit to NICE for approval on the NHS with Biogen extending their MAA by a year.

    Read more